Phase Ⅱ clinical trial of Hetaplatin in treatment of advanced gastric cancer

GU Kang-sheng,XIONG Jian-ping
DOI: https://doi.org/10.3969/j.issn.1001-1692.2005.06.005
2005-01-01
Abstract:Objective To evaluate the efficacy and safety of Hetaplatin and combination therapy in patients with advanced gastric cancer.Method An open prospective randomized controlled phase Ⅱ clinical trial on Hetaplatin was conducted multicenterally.In H group the patients were treated with Hetaplatin 360 mg/m~2 d1,in H/5-FU/CF group the patients were treated with Hetaplatin in combination with 5-FU and Folinic acid,and in C/5-FU/CF group the patients were treated with Cisplatin combined with 5-FU/CF.In last two groups 5-FU 375 mg/m~2 and CF 200 mg/m~2 were given as infusion for 5 consecutive days;in H/5-FU/CF group 360 mg/m~2Hetaplatin was given in d1,and in C/5-FU/CF group Cisplatin 25 mg/m~2was solved in 0.9% normal saline 500 ml and given as infusion for 3 consecutive days.In all three groups treatment was recycled every 3 weeks.The response to treatment was evaluated according to WHO criteria in the third week after two courses,and the safety was evaluated according to NCIC CTG criteria.Results Two hundred patients were analyzed for response,the overall response rates were 14.9%,22.8% and 22.0% in sole Hetaplatin,combination trial and combination control groups,respectively;there were no significant differences between two combination groups.The hematologic toxicity was mild and non-hematologic toxic responses were strong including nausea/vomiting and declined appetite in Hetaplatin sole group.The hematologic toxicity in H/5-FU/CF group was lower and non-hematologic toxicity was higher compared with those of C/5-FU/CF group,however there were no statistical significant differences between two groups.Conclusions Hetaplatin is safe and effective in treatment of patients with advanced gastric cancer.The response rate and side effect are similar in combination of Hetaplatin or Cisplatin with 5-FU/CF for the treatment of advanced gastric cancer.
What problem does this paper attempt to address?